Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2015

View Archived Issues

MI-mAbs immunotechnology center launched in France

EMD Serono amends agreement with Opexa to support Tcelna development

Radius Health acquires license to develop and market RAD-1901 in Japan

Spry-2 shows potential as a prognostic biomarker in ovarian cancer

MazF-modified T cells are safe and persistant in aviremic HIV patients

Novel HPV vaccine increases seroconversion levels after each vaccination

TWi Biotechnology receives rare disease drug designation for AC-203 in Taiwan

MedImmune and Joslin Diabetes Center form new collaboration for metabolic disease research

LDC receives grants to develop new drug candidates

Illumina and Merck Serono collaborate to develop universal NGS-based oncology diagnostic

Novel crossmab antibody shows efficacy in neovascular disease of the eye

Madison Vaccines confirms program expansions for prostate cancer vaccines

Stratatech reports topline results from proof-of-concept study of StrataGraft skin tissue

Merrimack uses RNAscope to select patients for phase II NSCLC trial of MM-121

Halozyme Therapeutics selects first product candidate under Janssen collaboration

Boehringer Ingelheim divulges BRD4/HUNK1 inhibitors

FDA accepts for review Spectrum's Captisol-Enabled Melphalan NDA

Multi-kinase inhibitor shows potential for AMD

Ocular Therapeutix reports phase III results for dexamethasone punctal plug

FDA approves Unituxin for pediatric patients with high-risk neuroblastoma

Merck & Co.'s pembrolizumab is first drug accepted in U.K. Early Access to Medicines Scheme

Ophthotech achieves new milestone under Fovista agreement with Novartis

Interim analysis completed for phase III trial of AM-101 in post-acute tinnitus

Merck & Co. patents PAR-1 antagonists

Allergan describes S1P1 receptor modulators

Roche and Genetech disclose MAP3K14 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...